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The PLoS Medicine Debate
What Should Be Done To Tackle 
Ghostwriting in the Medical Literature?
Peter C. Gøtzsche, Jerome P. Kassirer, Karen L. Woolley, Elizabeth Wager, Adam Jacobs, Art Gertel, Cindy Hamilton
B
ackground to the debate: Ghostwriting occurs when 
someone makes substantial contributions to a 
manuscript without attribution or disclosure. It is considered 
bad publication practice in the medical sciences, and some 
argue it is scientific misconduct. At its extreme, medical 
ghostwriting involves pharmaceutical companies hiring 
professional writers to produce papers promoting their 
products but hiding those contributions and instead naming 
academic physicians or scientists as the authors. To improve 
transparency, many editors’ associations and journals allow 
professional medical writers to contribute to the writing of 
papers without being listed as authors provided their role 
is acknowledged. This debate examines how best to tackle 
ghostwriting in the medical literature from the perspectives 
of a researcher, an editor, and the professional medical 
writer.
Viewpoint by Peter C. Gøtzsche: Ghostwriting 
Is Scientific Misconduct and Should Be Handled 
Accordingly
Scientific communication depends on trust. We should be 
able to believe what we read, and trust that knowledge when 
we plan experiments and treat patients. Unfortunately, 
we cannot. Conflicts of interest are ubiquitous; billions of 
dollars are being earned undeservedly by drug companies 
through flaws in research, research articles, reviews, and 
editorials; and many academic careers have also been built 
on doubtful evidence. The recent stream of books about the 
corruptive influence of money on health care research and 
practice, some of which have been written by editors of our 
most prestigious journals [1–3], illustrates just how bad the 
situation is. 
Part of the problem is that good names give papers 
credibility. A colleague once told me that in his country it was 
more important to know the authors than the methods of a 
research paper, as some professors lent their names to almost 
anything if they were well paid. I have seen single-authored 
meta-analyses on drugs presenting sophisticated analyses that 
went far beyond the capability of the author, without a word 
about who did the analyses (and presumably even wrote the 
paper). Similarly, many drug reviews are unlikely to have 
been written by the authors, as these professors probably have 
more important things to do than writing book-length drug 
reviews in sponsored supplements or peripheral journals that 
few would ever read and that have no impact factor. 
Ghost authorship exists when someone has made 
substantial contributions to writing a manuscript and this role 
is not mentioned in the manuscript itself [4]. It often occurs 
simultaneously with its opposite, guest authorship (sometimes 
called honorary or gift authorship), where the contributions 
of the named authors are so small, or nonexistent, that they 
do not merit authorship [5,6].
Court cases that allowed access to industry files have shown 
that ghost and guest authorship are common, even in our 
best journals [5,6]. But misappropriation of authorship is 
dishonest [4] and is regarded as scientific misconduct in 
some jurisdictions like Denmark, where the law states that 
misappropriation of author role, either deliberately or 
through serious neglect, is a type of scientific misconduct 
[7]. Regrettably, it is rarely detected. The involved parties 
have a common interest in secrecy, and junior researchers 
can ruin their careers if they reveal that the professor did 
not write the papers that bear his or her name. It is still 
commonly accepted that department chairs claim authorship 
of all papers emanating from the department, and newspaper 
articles celebrating a professor’s 60th birthday may note that 
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he or she has written more than 500 papers. The professor 
may have contributed, but almost certainly wrote only a 
minority of them.
I have some suggestions that might reduce the prevalence 
of misappropriated authorship:
1. Most importantly, all journal articles should list the 
contributions of the authors [8]. This would make it far 
easier for authors and editors to object before publication, 
and to document cheating after publication. 
2. Editors should explain in their “Instructions to Authors” 
that ghost and guest writing is scientific misconduct and 
will be exposed if detected, possibly alerting the authors’ 
academic institutions, and identifying the commercial 
companies [4]. Editors’ associations, such as the 
Committee on Publication Ethics, the Council of Science 
Editors, the International Committee of Medical Journal 
Editors (ICMJE), and the World Association of Medical 
Editors (WAME), should develop policies that recommend 
ghostwriting be deemed scientific misconduct.
3. Editors should ask authors to specify who wrote the first 
draft of the paper (and for research studies, who wrote 
the protocol and did the statistical analyses [5]), and 
should contact these people to confirm their contribution 
if they are not authors. Editors should be particularly 
careful when manuscripts concern drugs or medical 
devices.
4. Editors should not accept meaningless statements in 
the Acknowledgments such as “We thank XX” (without 
specifying for what) or “XX provided editorial assistance” 
(a euphemism, usually without affiliation, for “XX from 
Company YY wrote the paper”).
5. Guidelines on good publication practices for drug 
companies [9] and medical journals [4,10] should be 
followed.
6. Authors should retain copies of drafts to facilitate 
investigations of possible misconduct. 
7. To ensure accountability, ethical review committees and 
drug agencies should not accept protocols that have no 
named authors, although this is very common [5].
8.To properly document misconduct, journals and 
PubMed should use the term “misappropriated 
authorship.” Currently, this type of misconduct is listed 
under “erratum,” but it is rarely an error. It is usually 
deliberate. 
9. Finally, editors should insist that medical writers be 
authors. The European Medical Writers Association has 
stated that writers usually do not qualify for authorship, 
although their role should be acknowledged [11], and 
Wager has argued, with reference to the ICMJE criteria, 
that many writers feel they do not fulfill the principle that 
authors should be able to take public responsibility for 
the study [11]. However, these criteria only specify that 
each author should have participated sufficiently in the 
work to take public responsibility for appropriate portions 
of the content [10]. As it is not possible to write a paper 
without judgment and interpretation of data, which Wager 
recognizes [11], writers fulfill the authorship criteria 
[5,10].
To put it simply: if a cook isn’t cooking, what is a cook then 
doing?
Viewpoint by Jerome P. Kassirer: Ghostwriting Is 
Difficult To Define, and We Need More Evidence 
of Its Frequency and Impact 
Ghostwriting debases fundamental tenets of the medical 
profession. It violates authors’ personal integrity, 
responsibility, and accountability. More importantly, 
ghostwriting threatens the very fabric of science and thus 
the validity of our medical knowledge, and in doing so it 
jeopardizes patient care. 
Denouncing ghostwriting is easy; defining its variants is 
not. At the extreme, ghostwriting is easy to define. Perhaps 
the most egregious example is that of a pharmaceutical 
company’s marketing department promoting one of its 
products by carefully selecting positive reports and de-
emphasizing the product’s risks, and then paying a well-
known academic author to submit the paper for publication 
without attribution [6]. Few would disagree that this 
behavior is inappropriate, unprofessional, unacceptable, and 
potentially dangerous. Lesser degrees of ghost involvement in 
the writing process are also problematic, such as permitting 
the commercial sponsor of a clinical trial to collect and 
hold all of the trial’s data, providing exclusive statistical 
expertise and final tables for publication, drafting a complete 
manuscript of a study it supported, or insisting contractually 
on the last say on the final manuscript’s content and 
conclusions.
Other kinds of ghost involvement are more ambiguous. Is 
it acceptable to hire a science writer to interview a physician 
and write a paper on that subject, which the physician then 
calls his or her own? Is it appropriate for a scientist in a 
company to analyze a portion of evidence, write a draft of the 
information, and then for another author to incorporate that 
draft into a manuscript without crediting the scientist? Is it 
acceptable for a physician-researcher to pay someone to do 
the same? How much help with writing is okay? Where do we 
draw the line in some of these fringe areas of ghostwriting?
Because many interactions between academics and 
industry in developing, testing, and reporting on new 
products are desirable, such authorship definitions are 
critical. Unfortunately, there is not a great deal of uniformity 
among journals (the major publishing gatekeepers) in what 
constitutes an acceptable contribution. The guidelines of the 
ICMJE and WAME provide a good start [4,10]. They define 
an author as someone who has made substantial contributions 
to conception and design, or acquisition of data, or analysis 
and interpretation of data; has drafted the article or revised 
for important intellectual content; and has given approval 
of the final version. More stringent requirements may be 
necessary, however. Some journals require that authors have 
had full control of the primary data, have carried out the 
statistical tests themselves (e.g., JAMA), and have created 
tables and figures themselves. Others require that each 
author state the specific contributions they have made to the 
study or to the writing of the manuscript, and some journals 
publish these (e.g., BMJ, PLoS Medicine).
Other journals review components of study protocols that 
are vulnerable to manipulation by the sponsor and will only 
publish clinical trials that are registered in a public database 
endorsed by the ICMJE. Increasingly, journals require that 
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and in addition will not accept papers unless the decision to 
publish is controlled by the researchers. Finally, one former 
editor, Richard Smith, thinks that the entire peer review 
system should be scrapped because of excessive industry 
influence on publishing [12]. He would replace the current 
system by an open, Web-based disclosure of protocols, data, 
and statistical assessment, with publication only of systematic 
reviews based on the study data [13]. These tactics go some 
way toward stemming ghost involvement in the publication 
process.
Any additional “cure” for ghostwriting must take into 
account its frequency and impact. Information from 
questionnaire studies suggests that authorship in up to 10% 
of published papers could be attributed to ghostwriters 
[14–17], although the fraction in industry-sponsored clinical 
trials in one study was considerably higher [5]. In trying to 
understand the prevalence, we are stymied because we just 
don’t know what we don’t know. Moreover, most of the data 
in these studies are self-reported, and the exact frequency 
of company-inspired writing is well hidden. And finally, the 
impact of ghostwriting is even more difficult to estimate. 
For this reason, we must be careful not to impose excessive 
regulations to solve problems that may not be threatening.
Nonetheless, editors of medical journals could devote more 
effort to define what constitutes appropriate and inappropriate 
participation in studies and manuscript preparation, especially 
by companies with products at stake. At the very least, editors 
can demand transparency. Who were the trial designers? 
Who were the trial conductors, the researchers, and the data 
managers? Who did the statistics? Who wrote the manuscript 
and who signed off on the final draft? Can all authors take 
public responsibility for their roles?
Overtly biased ghostwritten articles can cause patient harm; 
others damage the public’s trust in both the pharmaceutical 
industry and the medical profession. Loss of trust may be 
ghostwriting’s major victim. Neither the industry nor the 
profession can afford further damage to their reputations. 
Both should “just say no” to ghostwriting.
Viewpoint by Karen L. Woolley, Elizabeth Wager, 
Adam Jacobs, Art Gertel, and Cindy Hamilton: 
Professional Medical Writers Can Be Legitimate 
Contributors to Manuscripts, But Ghostwriting Is 
Dishonest and Unacceptable 
Professional medical writers have been recognized by medical 
journal editors as legitimate contributors to manuscripts 
[4,10], but concerns remain about “ghostwriting,” namely 
the failure to disclose such contributions. Professional 
medical writers, who must be distinguished from ghostwriters 
[18], could be valuable allies to those determined to 
eradicate ghostwriting. Professional medical writers have 
communication expertise and health care knowledge, and 
abide by ethical guidelines for medical writers. They assist 
authors to prepare documents (e.g., abstracts, slides, posters, 
and manuscripts), but ensure that the authors control the 
content and that appropriate disclosures of funding and 
involvement are made. We believe that professional medical 
writers can offer unique, and too frequently untapped, insight 
into how to address ghostwriting. We offer the perspective 
of professional medical writers on three strategies that have 
been considered for tackling ghostwriting.
Strategy #1: Why Don’t We Ban Medical Writers?
In 2005, the Editorial Board of the Clinical Journal of Oncology 
Nursing tried to challenge ghostwriting by rejecting “…
manuscripts that have been written by medical writers or 
communication companies” [19]. This strategy has not 
been embraced by many editors. Instead, the Council of 
Science Editors, the ICMJE, and WAME strive to discourage 
ghostwriting by requiring authors to disclose medical writing 
assistance and funding. 
We support disclosure, rather than prohibition. Banning 
medical writers could have unintended consequences. For 
example, a ban could intensify the ethical and scientific 
problem of nonpublication. Only 50% of medical research 
results may ever be published in full [20], and limited 
writing time is one of the main reasons for nonpublication 
[16]. Professional medical writers can help authors avoid 
nonpublication by completing many of the time-consuming 
manuscript preparation tasks [18,21]. Encouraging, rather 
than banning, medical writer involvement may be particularly 
important for helping authors and sponsors reduce the rate 
of nonpublication (23%) associated with industry-sponsored 
clinical trials [22].
Banning medical writers could also reduce the quality 
of manuscripts, particularly if authors have limited time, 
manuscript writing experience, English language skills, or 
awareness of reporting guidelines. Professional medical 
writers have the specialist skills required to help authors 
communicate in a clear, concise, and credible manner, 
and to ensure manuscripts meet journal requirements 
[9,18,21,23,24]. Banning writers may increase the number of 
poorly prepared or noncompliant manuscripts—a prospect 
not likely to be welcomed by editorial staff or peer reviewers.
Just as some researchers need statistical assistance, some 
researchers need writing assistance. We, like the Council of 
Science Editors, the ICMJE, and WAME, believe that such 
assistance should be disclosed, but not banned.
Strategy #2: Why Don’t We Develop More Guidelines?
We don’t believe that more guidelines are needed; indeed, we 
assert that existing guidelines already emphasize the need for 
appropriate disclosure of writing assistance. The consistency 
among these guidelines is remarkable, given that they have 
been developed by different stakeholders, including journal 
editors [4,10], medical writers [9,18,21,23,24], and industry 
[25]. Despite these guidelines, the appropriate disclosure 
of medical writing assistance is low [16]. Many authors 
don’t have the time or inclination to keep up-to-date with 
guidelines. In some instances, appropriate disclosure may 
only occur because professional medical writers alert authors 
to their responsibilities. Banning writers or creating more 
guidelines could exacerbate an already problematic situation. 
An alternative strategy is required to tackle ghostwriting.
Strategy #3: Is There Anything Practical We Can Do?
One of the most practical ways to tackle ghostwriting could 
be the mandatory use of a checklist that could help editors 
detect ghostwriting and help authors avoid ghostwriters. We 
consulted professional medical writers and editors in Europe, 
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checklist (Table 1) that could be completed by all authors 
who used medical writers. 
This checklist prompts authors to acknowledge professional 
medical writers and their funding source, to confirm that 
the authors controlled the main points, outcomes, and data 
reported in the manuscript, and to verify that medical writers 
could provide evidence that guidelines on ethical writing 
practices were followed. The checklist balances brevity with 
utility. Editors could always ask authors additional questions. 
The checklist, which could be included in journals’ 
“Instructions to Authors,” could help editors encourage 
appropriate disclosure of writing assistance, as well as raise 
awareness of existing guidelines. The checklist is a logical 
extension of journal editors’ gatekeeping role. By putting the 
onus of use on authors, the checklist could be implemented 
quickly and without the need for extensive resources. The 
checklist would also provide sponsors and professional medical 
writers with a means of documenting appropriate medical 
writing use. Indeed, an audit trail of appropriate interactions 
between authors and professional medical writers should be 
available. Organizations trying to eradicate ghostwriting could 
educate their members about the checklist.
In conclusion, we believe the debate about ghostwriting 
needs to shift from whether authors used writers to 
whether writing assistance was appropriate and adequately 
disclosed. Professional medical writers are trained to provide 
appropriate assistance and to insist on disclosure. Since 
professional medical writers work with experienced and 
inexperienced authors from around the world on a daily 
basis, they could be valuable allies in the efforts to tackle 
ghostwriting.  
Supporting Information
Table S1. Checklist for Authors Using Medical Writers
Found at doi:10.1371/journal.pmed.1000023.st001 (32 KB DOC).
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Table 1. Checklist for Authors Using Medical Writers: A Practical Tool to Discourage Ghostwriting
Professional medical writers can be legitimate contributors to manuscripts, but ghostwriting is dishonest and unacceptable.
Authors: If a medical writer contributed to the preparation of your manuscript, you must answer the questions below. 
Question Answer
No Yes
1 (a) Did the medical writer meet the three criteria for authorship, as specified by the ICMJE ? 
(b) If not, has the writer been identified in the acknowledgments or as directed by the journal? 
2 Has the source of funding for the medical writer’s services been identified in the acknowledgments or as directed by the journal? 
3 Did the author(s) make the final decision on the main points to be communicated in the manuscript, particularly in the conclusion?
4 Did the author(s) make the final decision on the primary and secondary outcomes and relevant data to be reported in the manuscript?
5 If requested by the journal, can the medical writer provide evidence that the manuscript was prepared in accordance with international guidelines 
for ethical medical writing (e.g., Uniform Requirements for Manuscripts Submitted to Biomedical Journals [10]; Good Publication Practice for 
Pharmaceutical Companies [9]; Position Statements from the European or American Medical Writers  Associations or the International Society for 
Medical Publication Professionals [21])?
This checklist is available as an MS Word document in Table S1.
doi:10.1371/journal.pmed.1000023.t001